

AD\_\_\_\_\_

Award Number: DAMD17-03-1-0053

TITLE: A Chemoprevention Trial to Study the Effects of High Tea  
Consumption on Smoking-Related Oxidative Stress

PRINCIPAL INVESTIGATOR: Iman A. Hakim, M.D., Ph.D.

CONTRACTING ORGANIZATION: Arizona University  
Tucson, Arizona 85722-3308

REPORT DATE: February 2005

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20051229 017

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                 |                                                                |                                                                               |                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------------------------|-------------------------------------------------------------------------------|----------------------------------|
| <b>1. AGENCY USE ONLY</b><br>(Leave blank)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                 | <b>2. REPORT DATE</b><br>February 2005                         | <b>3. REPORT TYPE AND DATES COVERED</b><br>Annual (13 Jan 2004 - 12 Jan 2005) |                                  |
| <b>4. TITLE AND SUBTITLE</b><br>A Chemoprevention Trial to Study the Effects of High Tea Consumption on Smoking-Related Oxidative Stress                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                 |                                                                | <b>5. FUNDING NUMBERS</b><br>DAMD17-03-1-0053                                 |                                  |
| <b>6. AUTHOR(S)</b><br>Iman A. Hakim, M.D., Ph.D.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                 |                                                                |                                                                               |                                  |
| <b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b><br>Arizona University<br>Tucson, Arizona 85722-3308<br><br><i>E-Mail:</i> ihakim@azcc.arizona.edu                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                 |                                                                | <b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>                               |                                  |
| <b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b><br>U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                 |                                                                | <b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>                       |                                  |
| <b>11. SUPPLEMENTARY NOTES</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                 |                                                                |                                                                               |                                  |
| <b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b><br>Approved for Public Release; Distribution Unlimited                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                 |                                                                |                                                                               | <b>12b. DISTRIBUTION CODE</b>    |
| <b>13. ABSTRACT (Maximum 200 Words)</b><br><p>Our overall goal is to develop a safe and feasible model for the chemoprevention of a wide range of tobacco-related diseases. Our immediate goal, that is addressed over a 4-year study period, is to determine the effects of high tea consumption on biological markers of oxidative stress that mediate lung cancer risk. We are conducting a 6-month randomized, controlled, double-blinded chemopreventive trial in a group of COPD subjects who are being randomized to green or black tea preparations or a control intervention (matching placebo). Levels of 8-hydroxydeoxyguanosine and 8-F2-isoprostanes will be used to measure DNA and lipid damage respectively. Changes in biomarkers of oxidative damage will be measured in urine, blood and exhaled breath condensate. The study protocol was approved by all parties in September 2003. Recruitment and screening of participants for eligibility criteria started in October 2003. By the end of December, 110 participants signed the consent form and were screened for eligibility criteria (spirometry for lung function). Eight subjects with FEV1 &gt; 85% of the standard were excluded from the study and 20 subjects dropped out during run-in and before randomization. Currently 37 eligible subjects were enrolled in the study and 32 subjects have already completed the 6-month intervention. We expect that adherence to a regular pattern of tea is feasible and quantifiable among this high risk population.</p> |                                                                 |                                                                |                                                                               |                                  |
| <b>14. SUBJECT TERMS</b><br>Chemo-preventative approaches to smoking related illness                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                 |                                                                |                                                                               | <b>15. NUMBER OF PAGES</b><br>14 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                 |                                                                |                                                                               | <b>16. PRICE CODE</b>            |
| <b>17. SECURITY CLASSIFICATION OF REPORT</b><br>Unclassified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | <b>18. SECURITY CLASSIFICATION OF THIS PAGE</b><br>Unclassified | <b>19. SECURITY CLASSIFICATION OF ABSTRACT</b><br>Unclassified | <b>20. LIMITATION OF ABSTRACT</b><br>Unlimited                                |                                  |

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)  
Prescribed by ANSI Std. Z39-18  
298-102

## Table of Contents

|                                   |       |
|-----------------------------------|-------|
| Cover.....                        | 1     |
| SF 298.....                       | 2     |
| Introduction.....                 | 4     |
| Body.....                         | 4-12  |
| Key Research Accomplishments..... | 12    |
| Reportable Outcomes.....          | 12    |
| Conclusions.....                  | 13    |
| References.....                   | 13    |
| Appendices.....                   | 13-14 |

## INTRODUCTION

Preventive strategies require identification of cancer-susceptible individuals resulting from combinations of carcinogen exposure and lack of protective factors. Oxidative reactions have been implicated as important modulators of human health and can play a role in both disease prevention and disease development. A large number of studies have demonstrated an increased oxidant burden and consequently increased markers of oxidative stress in the airspaces, breath, blood, and urine of smokers and of patients with chronic obstructive pulmonary disease (COPD) [1,2]. Changes in dietary habits with the intake of more cancer-chemopreventive agents appear to be a practical approach for cancer prevention in subjects with increased oxidative stress as is the case of subjects with COPD and  $\geq 25$  pack/year of smoking history.

The present study will investigate the ability of regular green and /or black tea consumption to decrease oxidative stress during the context of a randomized, controlled, double blinded, dietary intervention trial. Levels of 8-hydroxydeoxyguanosine (8-OHdG) will be used to measure DNA damage and levels of 8-F2 isoprostanes (8-epi-PGF2) and ethanes will be used to measure lipid damage. Testing for biomarkers of oxidative stress in exhaled breath condensate (EBC) will complement other innovative methods currently being investigated. The use of this novel strategy might enable further classification of people at risk of increased oxidative stress lung cancer, such as smokers, workers in nuclear weapons plants, Gulf War veterans [3], and US Marines by degree of risk. Such refinement of risk analysis might then be used to identify candidates for screening studies.

## BODY


### Task 1. Preparation, protocol development and analysis of tea extracts and placebo (QC/QA) for tea polyphenols (Months 1-7)

Completed: See previous report


### Task 2. Recruitment/ eligibility, Run-In & baseline assessment of oxidative stress (Month 8-36)

#### a & b) Potentially eligible subjects will be recruited beginning in month 5 of the study and continuing through the end of year 3 and complete baseline questionnaires.

A total of 863 subjects were interviewed by phone for eligibility criteria. Three hundred and eighty eight subjects were not eligible because of age, pack/year of cigarettes, medications, had cancer, or currently enrolled in another study. Three hundred sixty five subjects refused to participate (won't give up tea, cannot drink much tea, study too long).




By the end of January (2004), 110 participants signed the consent form and were screened for confirmation of COPD eligibility criteria (spirometry for lung function tests). Eight subjects with FEV1 > 85% of the standard were excluded from the study and the remaining 102 eligible subjects were enrolled in the study.



- c) Eligible subjects will complete 1-month run-in period during which they will consume the placebo beverage and complete all baseline questionnaires.




By the end of December (2004), 102 eligible subjects completed all baseline questionnaires and started the run-in period. Each enrolled participant, received 1-month of placebo tea bags, study teacup, a 3-minute timer, the monthly diary and health monitoring forms, and sterile urine cups. Subjects were contacted biweekly to ensure and encourage adherence and to monitor any adverse event.

Twenty of the participants dropped-out from the study in the first week. The main reported causes of drop-out are: 1) could not stop coffee, do not like the taste of the tea, and caffeine intolerance. To date, 69 participants have completed and/or are completing the 1-month run-in.



**d & e )** Subjects who complete the run-in period will provide blood, urine and exhaled breath condensate (EBC) samples for biomarker analysis. Subjects will be asked to provide buccal cells and induced sputum samples for storage.

To-date 82 subjects completed the run-in successfully and were randomized to one of the study arms: Green tea, black tea, or placebo. All randomized subjects provided blood and urine samples, exhaled breath condensate (EBC), and buccal cell samples. Forty one of the randomized subjects provided sputum samples.




f) Determination of each subject's baseline history of smoking, diet and tea intake, plasma catechins, and levels biomarkers of oxidative stress at baseline.

All baseline data for enrolled participants were collected and all data was entered into the computer. Quality control of the data is performed regularly. This is an ongoing process with ongoing recruitment and enrollment.

**Task 3.** Intervention, Follow-up & Exit focus groups to study the effect of tea consumption on DNA (8-OHdG) and lipid (8-epi-PGF2) damage in blood, urine, and EBC (Months 10-43).

- a) Randomize eligible COPD chronic and former smokers into one of three interventions: black tea, green tea or placebo for 6 months.

To-date 69 subjects have been randomized to 1 of the 3 arms of the study. Thirty two subjects have already completed the 6-month intervention study and 37 are currently completing the study.



- b) To maintain high adherence to the study intervention including collection of blood, urinary, and EBC samples through the 6-month intervention period and 1-month follow-up period.

Study participants are contacted biweekly by phone to ensure adherence. Subjects complete a tea and smoking diary in which they report their daily intake of tea (amount and time) and the number of cigarettes smoked each day. They also complete a health monitoring form in which they report any change in medication use, any health-related event, or any perceived adverse event.

- c) To identify issues affecting recruitment and retention of chronic and former smokers with COPD in a lung cancer prevention trial.  
d) To determine whether subjects will continue to consume tea regularly after the end of the intervention.

Exit and satisfaction questionnaire were collected from all participants that completed the study. Data is being entered into the computer database. This is an ongoing process and final results will be available at the end of the study when randomization arm will be revealed. To date, the most common causes of drop-out are too much fluid and time commitment.

#### **Task 4.      Laboratory analyses and data entry (Months 8-45)**

##### **a) Quality control assurances of laboratory methods**

We have completed all the validation and quality control measures for the biomarkers of oxidative stress. Our quality control and validation data show that the urinary biomarkers of oxidative DNA and lipid damage are stable even when left at room temperature for 3 consecutive days.


##### **b) & c) Urinary and blood biomarkers' analyses and quality control**

Laboratory analyses of urinary and blood biomarkers of oxidative damage started on time as scheduled. All laboratory analyses undergo quality control/quality assurance measures before being sent for data entry. This preliminary summary represents the data that had been entered into our database. This is an ongoing process.

##### ***Measurements of 8-hydroxy-2'-deoxyguanosine (8OHdG) in human urine and lymphocyte DNA by high performance liquid chromatography-electrospray tandem mass spectrometry***

A method for quantification of 8OHdG in human urine by HPLC-tandem mass spectrometry has been implemented and validated in Dr. Chow's laboratory. The analysis is performed on a ThermoFinnigan TSQ Quantum triple quadrupole mass spectrometric system in tandem with a Surveyor LC system. The urine sample (50  $\mu$ l) is diluted 1:1 with water and injected onto the HPLC system. HPLC separation is achieved with a BDS Hypersil C<sub>18</sub> column (150 x 2.1 mm, 5 $\mu$ ) and a gradient mobile phase. The gradient starts at 1% methanol and 99% 10 mM ammonium formate and is increased linearly to 80% methanol and 20% ammonium formate by 15 minutes. The system is re-equilibrated with 1% methanol and 99% ammonium formate for 5 minutes before the next injection. The flow rate is 0.2 ml/min. 8OHdG (from precursor ion  $m/z$  284 to product ion  $m/z$  168) and 2'-deoxyguanosine (from precursor ion  $m/z$  268 to product ion  $m/z$  152) are detected with multiple reaction monitoring (MRM) in the positive ion mode utilizing electrospray ionization. Linear calibration curves have been established from 0.3 to 30 ng/ml (1-100 nM). The within-day and between-day coefficient of variation of the assay is less than 10%. 8OHdG is found to be stable in urine when stored at room temperature for 72 hours.

Dr. Chow's laboratory has also tested various DNA digestion procedures for measurement of 8OHdG levels in DNA to maximize release of normal nucleosides and 8OHdG and minimize oxidation of 2'-deoxyguanosine and DNA during sample preparation and handling. Dr. Chow's lab is currently optimizing procedures for isolating DNA from blood lymphocytes for 8OHdG measurements. Representative LC/MS/MS chromatograms for 8OHdG ( $m/z$  284/168) are presented below.




**LC/MS/MS chromatograms for 8OHdG ( $m/z$  284/168)**

A: Standard; B: baseline urine sample from subject 007; C: 3-month urine sample from subject 007; D: 6-month urine sample from subject 007.


***Measurements of 8-isoprostaglandin  $F_{2\alpha}$  (8-iso-PGF $_{2\alpha}$ ) in human urine by high performance liquid chromatography-electrospray tandem mass spectrometry***

A method for quantification of 8-isoprostaglandin  $F_{2\alpha}$  in human urine by HPLC-tandem mass spectrometry has been implemented and validated in Dr. Chow's laboratory. The analysis is performed on a ThermoFinnigan TSQ Quantum triple quadrupole mass spectrometric system in tandem with a Surveyor LC system. The urine sample (1 ml) is extracted with a solid phase extraction procedure before injecting onto the HPLC system. Isotope labeled 8-isoprostaglandin  $F_{2\alpha}$ -D4 (8-iso-PGF $_{2\alpha}$ -D4) is used as the internal standard. HPLC separation is achieved with a BDS Hypersil C $_{18}$  column (150 x 2.1 mm, 5 $\mu$ ) and a gradient mobile phase consisting of 2 mM ammonium acetate (A) and 5:95 methanol:acetonitrile (B). The gradient starts at 20% B and increases linearly to 35% B by 27 minutes. The system is re-equilibrated with 20% B for 10 minutes prior to the next injection. Flow rate is 0.2 ml/min. 8-iso-PGF $_{2\alpha}$  (from precursor ion  $m/z$  353 to product ion  $m/z$  193), 8-iso-PGF $_{2\alpha}$ -D4 (from precursor ion  $m/z$  357 to product ion  $m/z$  197), and

prostaglandin  $F_{2\alpha}$  (from precursor ion  $m/z$  357 to product ion  $m/z$  197) are detected with multiple reaction monitoring (MRM) in the positive ion mode utilizing electrospray ionization. Linear calibration curves have been established from 20 to 5000 pg/ml. The within-day and between-day coefficient of variation of the assay is less than 10%.



**Representative LC/MS/MS chromatograms of a baseline urine sample (subject 007).**  
The ion pairs of  $m/z$  353/193 and  $m/z$  357/197 were used to monitor  $8\text{-iso-PGF}_{2\alpha}$  and  $8\text{-iso-PGF}_{2\alpha}\text{-d}_4$  (as internal standard).



**Representative LC/MS/MS chromatograms of a 6-month urine sample (subject 007).**  
The ion pairs of m/z 353/193 and m/z 357/197 were used to monitor 8-iso-PGF<sub>2α</sub> and 8-iso-PGF<sub>2α</sub>-d<sub>4</sub> (as internal standard).

We have completed the urinary analyses of biomarkers of oxidative DNA damage (8-OHdG) and lipid damage (8-F<sub>2</sub> isoprostanes), and creatinine for the first group of subjects who completed the 6-month study. Biomarkers were measured at baseline, month 3 (mid-intervention), and month 6 (end of intervention). Because of the nature of the study (randomized and blinded), we will not be able to sort the data by randomization group until the end of the study, and hence, we will not be able to comment on the effect of tea drinking until the end of the study. Summary of the overall entered data is presented in the Table below.

| <u>Visit</u> | <u>Normalized Conc. of 8-OH dG</u>                     | <u>Normalized Conc. of 8-iso PGF</u>                    | <u>Conc. of Creatinine</u>             |
|--------------|--------------------------------------------------------|---------------------------------------------------------|----------------------------------------|
|              | <u>Mean ( Range)</u><br><u>(ng 8-OH/mg Creatinine)</u> | <u>Mean ( Range)</u><br><u>(pg 8-iso/mg Creatinine)</u> | <u>Mean ( Range)</u><br><u>(mg/mL)</u> |
| Baseline     | 2.2 (0.4-7.5)                                          | 206.5 (117.2-429.1)                                     | 0.8 (0.4-1.9)                          |
| Month 3      | 1.5 (0.8-2.6)                                          | 157.9 (45.4-280.2)                                      | 0.7 (0.3-1.4)                          |
| Month 6      | 1.9 (0.8-4.4)                                          | 183.5 (51.4-259.3)                                      | 0.6 (0.3-1.4)                          |

**d) Oxidative stress biomarkers in exhaled breath condensate**

***Measurements of 8-isoprostaglandin  $F_{2\alpha}$  (8-iso-PGF $_{2\alpha}$ ) in human exhaled breath condensate***

A commercially available enzyme immuno assay kit (Cayman Chemical, Catalog No. 516351) which has shown a limit of quantification of 4 pg/ml for measurements of 8-iso- PGF $_{2\alpha}$  levels in the breath condensate samples. We have established a reproducible 8-iso-PGF $_{2\alpha}$  calibration curve from 3.91 to 500 pg/ml. The between-day and within-day coefficient of variance is less than 11%. A number of baseline exhaled breath condensate samples were tested using this procedure and the 8-iso-PGF $_{2\alpha}$  levels were found to be at the low end of the calibration curve (2-4 pg/ml). To allow for more reliable determination of 8-iso-PGF $_{2\alpha}$  levels in exhaled breath condensate, we have applied a sample concentrating procedure to the breath condensate prior to the analysis. With a concentrating factor of 10, we were able to observe absorbance readings comparable to those observed with concentrations of 20-30 pg/ml. Because this is a more reliable concentration range to monitor any modulating effects from tea intervention, we plan to concentrate all exhaled breath condensate samples by a factor of 10 prior to sample analysis. Exhaled breath condensate samples are currently being analyzed.

***Measurements of Nitric Oxide (NO) and Ethane in Exhaled Air***

Measurements of NO and ethane in exhaled air is being done at baseline and month 6 ( end of intervention). All laboratory analyses undergo quality control/quality assurance measures before being sent for data entry. This preliminary summary represents the data that had been entered into our database. This is an ongoing process. Summary of the overall entered data is presented in the Table below.

| <u>Visit</u> | <u>Nitric Oxide (ppb)</u> | <u>Carbon Monoxide (ppm)</u> | <u>Ethane (ppb)</u> |
|--------------|---------------------------|------------------------------|---------------------|
|              | Mean ( Range)             | Mean ( Range)                | Mean ( Range)       |
| Baseline     | 24.3 (7.7- 59.4)          | 18.3 (1-58)                  | 4.6 (0.8-13.7)      |
| Month 6      | 14.2 (7.0 – 60.0)         | 15.9 (1-52)                  | 4.8 (1.2-19.9)      |

**KEY RESEARCH ACCOMPLISHMENTS**

- Development and approval of the study protocol
- Development and approval of all study forms and questionnaires
- Ongoing Successful recruitment and screening
- Ongoing Successful enrollment in the study
- Ongoing Successful collection of biological samples (blood, urine, EBC, buccal and sputum samples)
- Validation and quality control of all laboratory methods
- Ongoing laboratory analyses of biological samples.
- Thirty two participants successfully completed the study.
- Thirty seven participants are currently completing the study

**REPORTABLE OUTCOMES**

A Poster was presented in the Third Annual AACR International Conference “Frontiers in Cancer Prevention Research”, Seattle, Washington; October 16-20, 2004

## CONCLUSIONS

During this second year of the study, we were able to reach a large number of potential participants. We interviewed (initial screening) 863 subjects and randomized 82 eligible subjects in the study. Interviewing, initial screening, and enrollment are ongoing and we plan to enroll and randomize at least 50 participants this coming year.

Because tea is one of the most popular beverages consumed worldwide, the relationship between tea consumption and human cancer incidence is an important concern. Tea can be easily consumed with one's ordinary meals making compliance and adherence to dietary intervention more likely to succeed. Thus, the role of tea drinking as a potential inhibitor of carcinogenesis merits careful evaluation. We believe that a program of nutritional intervention with realistic dietary modifications that are effective, safe, and acceptable should be the cornerstone of any cancer prevention strategy.

## REFERENCES

1. Macnee W, Rahman . Oxidants and antioxidants as therapeutic targets in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1999 Nov; 160(5 Pt 2):S58-65.
2. MacNee W.. Oxidants/antioxidants and chronic obstructive pulmonary disease: pathogenesis to therapy. *Novartis Found Symp* 2001; 234:169-85; discussion 185-8.
3. Das AK. Davanzo LD. Poiani GJ. Zazzali PG. Scardella AT. Warnock ML. Edelman NH. Variable extrathoracic airflow obstruction and chronic laryngotracheitis in Gulf War veterans. *Chest*. 115(1):97-101, 1999.

## APPENDICES

1. Abstract entitled "A Chemoprevention Trial To Study The Effects Of High Tea Consumption On Smoking-Related Oxidative Stress"

## **A Chemoprevention Trial to Study the Effects of High Tea Consumption on Smoking-Related Oxidative Stress**

Iman A Hakim, H-H Sherry Chow, Linda Garland, Janine Einspahr, Richard Robbins, and Robin B Harris  
Arizona Cancer Center, University of Arizona, Tucson, AZ.

**BACKGROUND:** Oxidative reactions have been implicated as important modulators of human health and can play a role in both disease prevention and disease development. A large number of studies have demonstrated an increased oxidant burden and consequently increased markers of oxidative stress in the airspaces, breath, blood, and urine of smokers and of patients with chronic obstructive pulmonary disease (COPD). The overall goal of this study is to develop a safe and feasible clinical research approach that will serve as a model for the chemoprevention of a wide range of tobacco-related diseases. Our immediate goal, that is addressed over a 4-year study period, is to determine the effects of high tea consumption on biological markers of oxidative stress that mediate lung cancer risk, including, 8-hydroxydeoxyguanosine (8-OHdG), F2-isoprostanes (8-epi-PGF2), ethanes, and nitric oxide. We will also determine if high tea consumption can modulate the genes involved in the carcinogenic process in damaged bronchoepithelial cells. **METHODS:** We are conducting a 6-month randomized, controlled, double-blinded chemopreventive trial in a group of COPD subjects ( $FEV1 \leq 85\%$ ) with 25 or more pack-years of smoking history. The participants are stratified on smoking status (current or former) and gender, and are being randomized to green or black tea preparations or a control intervention (matching placebo). Levels of 8-OHdG will be used to measure DNA damage and levels of 8-epi-PGF2 and ethanes will be used to measure lipid damage. Changes in biomarkers of oxidative damage will be measured in urine, blood and exhaled breath condensate. Changes in the gene expression of biomarkers of proliferation (EGFR, PCNA, JUN, FOS, Ki-67) and apoptosis (bcl-2, caspase 3) in induced sputum will be assessed. **RESULTS:** The study protocol was approved by all parties in September 2003. Recruitment and screening of participants for eligibility criteria started in October 2003. By the end of August, 79 participants signed the consent form and were screened for eligibility criteria (spirometry for lung function tests). Eight subjects with  $FEV1 > 85\%$  of the standard were excluded from the study and the remaining eligible subjects were enrolled in the study. To date, 17 subjects have completed the study and 33 have been randomized and are completing the 6-month study. **CONCLUSION:** We expect that adherence to a regular pattern of tea is feasible and quantifiable among this high risk population.